Krystal is leveraging a validated, redosable platform with high margins, profitability, and multiple blockbuster catalysts in CF and NK. Read why KRYS is a Buy.
A first-in-human phase I/II study of GFH375, a highly selective and potent oral KRAS G12D inhibitor in patients with KRAS G12D mutant advanced solid tumors. This is an ASCO Meeting Abstract from the ...
Senior board officials, speaking on condition of anonymity, said the proposal is in the initial planning stage and will be ...
India Today on MSN
When will Skyroot launch India's first private Vikram-I rocket to space?
Senior officials at the company said the team is currently focused on flight-readiness checks of Vikram-I's integrated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results